JAZZ – Jazz Pharmaceuticals plc
Jazz Pharmaceuticals plcJAZZ
$248.24Name : Jazz Pharmaceuticals plc
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $15,934,290,944.00
EPSttm : 3.38
Jazz Pharmaceuticals plc
$248.24
1.14%$2.81
JAZZ — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
9.51
Margin Of Safety %
27
Put/Call OI Ratio
0.61
EPS Next Q Diff
10.96
EPS Last/This Y
6.56
EPS This/Next Y
11.05
Price
245.54
Target Price
299.24
Analyst Recom
1.42
Performance Q
-1.41
Upside
-57.9%
Beta
0.36
Ticker: JAZZ
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-10-12 | JAZZ | 216.78 | 0.54 | 1.83 | 4295 |
| 2026-10-13 | JAZZ | 210.38 | 0.53 | 0.32 | 4265 |
| 2026-10-14 | JAZZ | 209.68 | 0.40 | 0.30 | 3992 |
| 2026-10-15 | JAZZ | 214.38 | 0.36 | 0.01 | 3968 |
| 2026-10-16 | JAZZ | 210.25 | 0.31 | 0.04 | 4487 |
| 2026-10-19 | JAZZ | 208.42 | 0.40 | 1.71 | 3669 |
| 2026-10-20 | JAZZ | 213.68 | 0.41 | 0.64 | 3706 |
| 2026-10-21 | JAZZ | 211.73 | 0.41 | 0.01 | 3720 |
| 2026-10-22 | JAZZ | 214.61 | 0.39 | 0.00 | 3879 |
| 2026-10-23 | JAZZ | 213.97 | 0.19 | 0.01 | 6922 |
| 2026-10-26 | JAZZ | 205.63 | 0.19 | 0.02 | 6753 |
| 2026-10-27 | JAZZ | 206.78 | 0.19 | 0.02 | 6680 |
| 2026-10-28 | JAZZ | 205.03 | 0.19 | 1.00 | 6743 |
| 2026-10-29 | JAZZ | 207.73 | 0.19 | 0.30 | 6757 |
| 2026-10-30 | JAZZ | 215.99 | 0.19 | 65.66 | 6761 |
| 2026-11-02 | JAZZ | 214.72 | 0.89 | 0.41 | 10793 |
| 2026-11-03 | JAZZ | 229.77 | 0.89 | 4.58 | 11314 |
| 2026-11-04 | JAZZ | 234.63 | 0.61 | 0.41 | 10030 |
| 2026-11-05 | JAZZ | 227.35 | 0.61 | 0.14 | 10034 |
| 2026-11-06 | JAZZ | 234.68 | 0.61 | 0.25 | 10044 |
| 2026-11-09 | JAZZ | 243.56 | 0.61 | 0.04 | 10052 |
| 2026-11-10 | JAZZ | 245.46 | 0.61 | 0.19 | 10036 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-10-12 | JAZZ | 216.82 | -41.1 | 358.2 | 23.27 |
| 2026-10-13 | JAZZ | 210.21 | -41.1 | 333.2 | 23.27 |
| 2026-10-14 | JAZZ | 209.81 | -62.6 | 363.3 | 21.56 |
| 2026-10-15 | JAZZ | 214.45 | -62.6 | 387.3 | 21.56 |
| 2026-10-16 | JAZZ | 210.20 | -62.6 | 344.6 | 21.56 |
| 2026-10-19 | JAZZ | 208.40 | -62.6 | 357.0 | 21.56 |
| 2026-10-20 | JAZZ | 208.40 | -62.6 | 357.0 | 21.56 |
| 2026-10-21 | JAZZ | 213.64 | -68.5 | 393.6 | 21.12 |
| 2026-10-22 | JAZZ | 214.59 | -71.2 | 380.5 | 20.50 |
| 2026-10-23 | JAZZ | 213.90 | -71.2 | 362.8 | 20.50 |
| 2026-10-26 | JAZZ | 205.64 | -75.8 | 323.8 | 20.50 |
| 2026-10-27 | JAZZ | 206.79 | -75.8 | 372.4 | 20.50 |
| 2026-10-28 | JAZZ | 205.03 | -75.8 | 357.1 | 20.50 |
| 2026-10-29 | JAZZ | 207.82 | -75.8 | 381.3 | 20.50 |
| 2026-10-30 | JAZZ | 216.18 | -88.3 | 410.5 | 19.49 |
| 2026-11-02 | JAZZ | 214.46 | -88.3 | 358.6 | 19.49 |
| 2026-11-03 | JAZZ | 229.93 | -100.0 | 907.8 | 15.63 |
| 2026-11-04 | JAZZ | 234.57 | -1.3 | 858.9 | 15.49 |
| 2026-11-05 | JAZZ | 227.29 | -1.3 | 803.7 | 15.49 |
| 2026-11-06 | JAZZ | 234.68 | -100.0 | 872.2 | 14.94 |
| 2026-11-09 | JAZZ | 243.54 | -100.0 | 877.2 | 14.94 |
| 2026-11-10 | JAZZ | 245.54 | -100.0 | 846.0 | 14.94 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-10-12 | JAZZ | -4.94 | -1.79 | 8.79 |
| 2026-10-13 | JAZZ | -4.95 | -1.79 | 8.79 |
| 2026-10-14 | JAZZ | -4.95 | -1.79 | 8.79 |
| 2026-10-15 | JAZZ | -4.95 | -1.79 | 8.79 |
| 2026-10-16 | JAZZ | -4.95 | -1.79 | 8.79 |
| 2026-10-19 | JAZZ | -4.95 | -1.81 | 8.79 |
| 2026-10-20 | JAZZ | -4.95 | -1.81 | 8.79 |
| 2026-10-21 | JAZZ | -4.95 | -1.81 | 8.79 |
| 2026-10-22 | JAZZ | -4.95 | -1.81 | 8.79 |
| 2026-10-23 | JAZZ | -4.95 | -1.81 | 8.79 |
| 2026-10-26 | JAZZ | -4.95 | -1.28 | 8.79 |
| 2026-10-27 | JAZZ | -4.95 | -1.28 | 9.40 |
| 2026-10-28 | JAZZ | -4.95 | -1.28 | 9.40 |
| 2026-10-29 | JAZZ | -4.95 | -1.28 | 9.40 |
| 2026-10-30 | JAZZ | -4.95 | -1.28 | 9.40 |
| 2026-11-02 | JAZZ | -4.95 | -0.59 | 9.40 |
| 2026-11-03 | JAZZ | -4.95 | -0.59 | 9.40 |
| 2026-11-05 | JAZZ | -5.22 | -0.59 | 9.51 |
| 2026-11-06 | JAZZ | -5.04 | -0.59 | 9.51 |
| 2026-11-09 | JAZZ | -5.09 | -0.35 | 9.51 |
| 2026-11-10 | JAZZ | -5.09 | -0.35 | 9.51 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-4.83
Avg. EPS Est. Current Quarter
6.56
Avg. EPS Est. Next Quarter
6.13
Insider Transactions
-5.09
Institutional Transactions
-0.35
Beta
0.36
Average Sales Estimate Current Quarter
1243
Average Sales Estimate Next Quarter
1140
Fair Value
312.39
Quality Score
78
Growth Score
87
Sentiment Score
88
Actual DrawDown %
7.8
Max Drawdown 5-Year %
-42
Target Price
299.24
P/E
83.25
Forward P/E
9.22
PEG
0.19
P/S
3.34
P/B
3.75
P/Free Cash Flow
9.71
EPS
2.95
Average EPS Est. Cur. Y
14.94
EPS Next Y. (Est.)
25.99
Target Price Estimates Raised
4
Target Price Estimates Lowered
Profit Margin
4.37
Relative Volume
0.65
Return on Equity vs Sector %
-21.4
Return on Equity vs Industry %
-1.7
EPS 1 7Days Diff
-0.8
EPS 1 30Days Diff
-3.21
EBIT Estimation
846
◆
JAZZ
Healthcare
$245.43
Swing / Pullback
Buy the dip on strong trends
WATCH
RSI
66.5
Range 1M
99.9%
Sup Dist
3.2%
Momentum Growth
Ride accelerating trends
WATCH
EPS Yr
78.7%
EPS NY
77.7%
52W%
84%
Long-Term Value
Quality companies, undervalued
WATCH
🟢 BUY
+147.9% upside
Upside
+147.9%
Quality
78
MoS
27%
JAZZ — P/E HistoricalBiotechnology
Jazz Pharmaceuticals plcSector: Healthcare
Industry: Biotechnology
Employees: 2890
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Modeyso for the treatment of diffuse midline glioma harboring an H3 K27M mutation; and Defitelio to treat severe veno-occlusive disease. It also develops Zanidatamab in Phase 3 trial to treat HER2-positive gastroesophageal adenocarcinoma (GEA) and biliary tract cancers (BTC); Dordaviprone to treat H3 K27M-mutant diffuse glioma; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia. In addition, the company is developing Zanidatamab to treat neoadjuvant and adjuvant breast cancer; Vyxeos for the treatment of High-risk MDS, newly diagnosed untreated patients with high-risk AML, and De novo intermediate or adverse risk AML stratified by genomics; and JZP3507 to treat pheochromocytoma and paraganglioma that are in Phase 2 clinical trials. Further, it develops JZP815 to treat Raf and Ras mutant tumors; JZP898 for the IFN INDUKIN molecule in solid tumors; and JZP047 to treat absence epilepsy that are in Phase 1 clinical trials. The company collaboration agreements with Redx Pharma plc, Autifony Therapeutics Limited, Zymeworks Inc., Sumitomo Pharma Co., Ltd., Werewolf Therapeutics, Inc; and AbCellera Biologics Inc. Jazz Pharmaceuticals plc was founded in 2003 and is headquartered in Dublin, Ireland.
JAZZ
Latest News
—
Caricamento notizie per JAZZ…
stock quote shares JAZZ – Jazz Pharmaceuticals plc Stock Price stock today
news today JAZZ – Jazz Pharmaceuticals plc stock forecast ,stock prediction 2023 2024 2025
marketwatch JAZZ – Jazz Pharmaceuticals plc yahoo finance google finance
stock history JAZZ – Jazz Pharmaceuticals plc invest stock market
stock prices JAZZ premarket after hours
ticker JAZZ fair value insiders trading
Jazz Pharmaceuticals plcJAZZ
$248.24Name : Jazz Pharmaceuticals plc
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $15,934,290,944.00
EPSttm : 3.38
Jazz Pharmaceuticals plc
$248.24
1.14%$2.81
JAZZ — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
9.51
Margin Of Safety %
27
Put/Call OI Ratio
0.61
EPS Next Q Diff
10.96
EPS Last/This Y
6.56
EPS This/Next Y
11.05
Price
245.54
Target Price
299.24
Analyst Recom
1.42
Performance Q
-1.41
Upside
-57.9%
Beta
0.36
Ticker: JAZZ
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-10-12 | JAZZ | 216.78 | 0.54 | 1.83 | 4295 |
| 2026-10-13 | JAZZ | 210.38 | 0.53 | 0.32 | 4265 |
| 2026-10-14 | JAZZ | 209.68 | 0.40 | 0.30 | 3992 |
| 2026-10-15 | JAZZ | 214.38 | 0.36 | 0.01 | 3968 |
| 2026-10-16 | JAZZ | 210.25 | 0.31 | 0.04 | 4487 |
| 2026-10-19 | JAZZ | 208.42 | 0.40 | 1.71 | 3669 |
| 2026-10-20 | JAZZ | 213.68 | 0.41 | 0.64 | 3706 |
| 2026-10-21 | JAZZ | 211.73 | 0.41 | 0.01 | 3720 |
| 2026-10-22 | JAZZ | 214.61 | 0.39 | 0.00 | 3879 |
| 2026-10-23 | JAZZ | 213.97 | 0.19 | 0.01 | 6922 |
| 2026-10-26 | JAZZ | 205.63 | 0.19 | 0.02 | 6753 |
| 2026-10-27 | JAZZ | 206.78 | 0.19 | 0.02 | 6680 |
| 2026-10-28 | JAZZ | 205.03 | 0.19 | 1.00 | 6743 |
| 2026-10-29 | JAZZ | 207.73 | 0.19 | 0.30 | 6757 |
| 2026-10-30 | JAZZ | 215.99 | 0.19 | 65.66 | 6761 |
| 2026-11-02 | JAZZ | 214.72 | 0.89 | 0.41 | 10793 |
| 2026-11-03 | JAZZ | 229.77 | 0.89 | 4.58 | 11314 |
| 2026-11-04 | JAZZ | 234.63 | 0.61 | 0.41 | 10030 |
| 2026-11-05 | JAZZ | 227.35 | 0.61 | 0.14 | 10034 |
| 2026-11-06 | JAZZ | 234.68 | 0.61 | 0.25 | 10044 |
| 2026-11-09 | JAZZ | 243.56 | 0.61 | 0.04 | 10052 |
| 2026-11-10 | JAZZ | 245.46 | 0.61 | 0.19 | 10036 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-10-12 | JAZZ | 216.82 | -41.1 | 358.2 | 23.27 |
| 2026-10-13 | JAZZ | 210.21 | -41.1 | 333.2 | 23.27 |
| 2026-10-14 | JAZZ | 209.81 | -62.6 | 363.3 | 21.56 |
| 2026-10-15 | JAZZ | 214.45 | -62.6 | 387.3 | 21.56 |
| 2026-10-16 | JAZZ | 210.20 | -62.6 | 344.6 | 21.56 |
| 2026-10-19 | JAZZ | 208.40 | -62.6 | 357.0 | 21.56 |
| 2026-10-20 | JAZZ | 208.40 | -62.6 | 357.0 | 21.56 |
| 2026-10-21 | JAZZ | 213.64 | -68.5 | 393.6 | 21.12 |
| 2026-10-22 | JAZZ | 214.59 | -71.2 | 380.5 | 20.50 |
| 2026-10-23 | JAZZ | 213.90 | -71.2 | 362.8 | 20.50 |
| 2026-10-26 | JAZZ | 205.64 | -75.8 | 323.8 | 20.50 |
| 2026-10-27 | JAZZ | 206.79 | -75.8 | 372.4 | 20.50 |
| 2026-10-28 | JAZZ | 205.03 | -75.8 | 357.1 | 20.50 |
| 2026-10-29 | JAZZ | 207.82 | -75.8 | 381.3 | 20.50 |
| 2026-10-30 | JAZZ | 216.18 | -88.3 | 410.5 | 19.49 |
| 2026-11-02 | JAZZ | 214.46 | -88.3 | 358.6 | 19.49 |
| 2026-11-03 | JAZZ | 229.93 | -100.0 | 907.8 | 15.63 |
| 2026-11-04 | JAZZ | 234.57 | -1.3 | 858.9 | 15.49 |
| 2026-11-05 | JAZZ | 227.29 | -1.3 | 803.7 | 15.49 |
| 2026-11-06 | JAZZ | 234.68 | -100.0 | 872.2 | 14.94 |
| 2026-11-09 | JAZZ | 243.54 | -100.0 | 877.2 | 14.94 |
| 2026-11-10 | JAZZ | 245.54 | -100.0 | 846.0 | 14.94 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-10-12 | JAZZ | -4.94 | -1.79 | 8.79 |
| 2026-10-13 | JAZZ | -4.95 | -1.79 | 8.79 |
| 2026-10-14 | JAZZ | -4.95 | -1.79 | 8.79 |
| 2026-10-15 | JAZZ | -4.95 | -1.79 | 8.79 |
| 2026-10-16 | JAZZ | -4.95 | -1.79 | 8.79 |
| 2026-10-19 | JAZZ | -4.95 | -1.81 | 8.79 |
| 2026-10-20 | JAZZ | -4.95 | -1.81 | 8.79 |
| 2026-10-21 | JAZZ | -4.95 | -1.81 | 8.79 |
| 2026-10-22 | JAZZ | -4.95 | -1.81 | 8.79 |
| 2026-10-23 | JAZZ | -4.95 | -1.81 | 8.79 |
| 2026-10-26 | JAZZ | -4.95 | -1.28 | 8.79 |
| 2026-10-27 | JAZZ | -4.95 | -1.28 | 9.40 |
| 2026-10-28 | JAZZ | -4.95 | -1.28 | 9.40 |
| 2026-10-29 | JAZZ | -4.95 | -1.28 | 9.40 |
| 2026-10-30 | JAZZ | -4.95 | -1.28 | 9.40 |
| 2026-11-02 | JAZZ | -4.95 | -0.59 | 9.40 |
| 2026-11-03 | JAZZ | -4.95 | -0.59 | 9.40 |
| 2026-11-05 | JAZZ | -5.22 | -0.59 | 9.51 |
| 2026-11-06 | JAZZ | -5.04 | -0.59 | 9.51 |
| 2026-11-09 | JAZZ | -5.09 | -0.35 | 9.51 |
| 2026-11-10 | JAZZ | -5.09 | -0.35 | 9.51 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-4.83
Avg. EPS Est. Current Quarter
6.56
Avg. EPS Est. Next Quarter
6.13
Insider Transactions
-5.09
Institutional Transactions
-0.35
Beta
0.36
Average Sales Estimate Current Quarter
1243
Average Sales Estimate Next Quarter
1140
Fair Value
312.39
Quality Score
78
Growth Score
87
Sentiment Score
88
Actual DrawDown %
7.8
Max Drawdown 5-Year %
-42
Target Price
299.24
P/E
83.25
Forward P/E
9.22
PEG
0.19
P/S
3.34
P/B
3.75
P/Free Cash Flow
9.71
EPS
2.95
Average EPS Est. Cur. Y
14.94
EPS Next Y. (Est.)
25.99
Target Price Estimates Raised
4
Target Price Estimates Lowered
Profit Margin
4.37
Relative Volume
0.65
Return on Equity vs Sector %
-21.4
Return on Equity vs Industry %
-1.7
EPS 1 7Days Diff
-0.8
EPS 1 30Days Diff
-3.21
EBIT Estimation
846
◆
JAZZ
Healthcare
$245.43
Swing / Pullback
Buy the dip on strong trends
WATCH
RSI
66.5
Range 1M
99.9%
Sup Dist
3.2%
Momentum Growth
Ride accelerating trends
WATCH
EPS Yr
78.7%
EPS NY
77.7%
52W%
84%
Long-Term Value
Quality companies, undervalued
WATCH
🟢 BUY
+147.9% upside
Upside
+147.9%
Quality
78
MoS
27%
JAZZ — P/E HistoricalBiotechnology
Jazz Pharmaceuticals plcSector: Healthcare
Industry: Biotechnology
Employees: 2890
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Modeyso for the treatment of diffuse midline glioma harboring an H3 K27M mutation; and Defitelio to treat severe veno-occlusive disease. It also develops Zanidatamab in Phase 3 trial to treat HER2-positive gastroesophageal adenocarcinoma (GEA) and biliary tract cancers (BTC); Dordaviprone to treat H3 K27M-mutant diffuse glioma; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia. In addition, the company is developing Zanidatamab to treat neoadjuvant and adjuvant breast cancer; Vyxeos for the treatment of High-risk MDS, newly diagnosed untreated patients with high-risk AML, and De novo intermediate or adverse risk AML stratified by genomics; and JZP3507 to treat pheochromocytoma and paraganglioma that are in Phase 2 clinical trials. Further, it develops JZP815 to treat Raf and Ras mutant tumors; JZP898 for the IFN INDUKIN molecule in solid tumors; and JZP047 to treat absence epilepsy that are in Phase 1 clinical trials. The company collaboration agreements with Redx Pharma plc, Autifony Therapeutics Limited, Zymeworks Inc., Sumitomo Pharma Co., Ltd., Werewolf Therapeutics, Inc; and AbCellera Biologics Inc. Jazz Pharmaceuticals plc was founded in 2003 and is headquartered in Dublin, Ireland.
JAZZ
Latest News
—
Caricamento notizie per JAZZ…
stock quote shares JAZZ – Jazz Pharmaceuticals plc Stock Price stock today
news today JAZZ – Jazz Pharmaceuticals plc stock forecast ,stock prediction 2023 2024 2025
marketwatch JAZZ – Jazz Pharmaceuticals plc yahoo finance google finance
stock history JAZZ – Jazz Pharmaceuticals plc invest stock market
stock prices JAZZ premarket after hours
ticker JAZZ fair value insiders trading